Lv41
508 积分 2022-03-18 加入
CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance
4小时前
已完结
Recent advances in Camptothecin-derived antibody-drug conjugates
5小时前
已完结
Development and optimization of a high-throughput LC-MS/MS method for the simultaneous determination of Exatecan and its Cathepsin B-sensitive prodrug, and ARV-825 in rat plasma: Application to pharmacokinetic study
17天前
已完结
Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers
17天前
已完结
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
20天前
已完结
A comprehensive description of VEGF-R1/2 small molecule inhibitors as anticancer agents
21天前
已完结
A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities
21天前
已完结
Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives
21天前
已完结
Advances in VEGFR Inhibitors: A Comprehensive Review of Novel AnticancerAgents
21天前
已完结
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
22天前
已完结
皖公网安备34019202002308
